Application No: To be Assigned

(Continuation of Application No. 09/922,895)

Merck Case No.: 19634YDACA

Page 3

## Amendment to the Claims

This listing of claims will replace all prior vrsions, and listings, of claims in the application:

- 1 35 (Canceled)
- 36. (New) An isolated nucleic acid which encodes a human eosinophil eotaxin receptor receptor, said nucleic acid having the nucleotide sequence as set forth in SEQ ID NO:2.
- 37. (New) The nucleic acid of Claim 36 which further comprises the nucleotide sequence as set forth in SEQ ID NO:3.
- 38. (New) The nucleic acid of Claim 36 which further comprises the nucleotide sequence as set forth in SEQ ID NO:4.
- 39. (New) A vector comprising a nucleic acid which encodes a human eosinophil eotaxin receptor receptor, said nucleic acid having the nucleotide sequence as set forth in SEQ ID NO:2.
- 40. (New) The vector according to Claim 39 which is selected from the group consisting of: plasmids, modified viruses, yeast artificial chromosomes, bacteriophages, cosmids and transposable elements.
- 41. (New) An isolated mammalian host cell comprising the vector according to Claim 39.
  - 42. (New) The host cell of Claim 41 which is from the AML14.3D10 cell line.
- 43. (New) A method to determine the presence of a compound which binds to a human eosinophil eotaxin receptor comprising:

Application No: To be Assigned

(Continuation of Application No. 09/922,895)

Merck Case No.: 19634YDACA

Page 4

(a) introducing a nucleic acid which encodes the human eosinophil eotaxin receptor which comprises the nucleotide sequence (SEQ ID NO:2) into a cell under conditions so that eosinophil eotaxin receptor is expressed;

- (b) introducing a detector molecule or a nucleic acid encoding a detector molecule into the cell, wherein the detector molecule is directly or indirectly responsive to a eosinophil eotaxin-ligand binding event;
- (c) contacting the cell with a compound suspected of binding to the eosinophil eotaxin receptor; and
- (d) determining whether the compound binds to the eosinophil eotaxin receptor by monitoring the detector molecule.
- 44. (New) The method of Claim 43 wherein the result of step (d) is compared to that obtained using a known ligand of the eosinophil eotaxin receptor.
- 45. (New) The method of Claim 44 wherein the known ligand of the eosinophil eotaxin receptor is eotaxin.
- 46. (New) The method of Claim 44 wherein the known ligand of the eosinophil eotaxin receptor is RANTES.
- 47. (New) The method of Claim 44 wherein the known ligand of the eosinophil eotaxin receptor is MCP-3.
- 48. (New) The method of Claim 43 wherein the eosinophil eotaxin receptor is expressed in a host cell which does not naturally express the human eosinophil eotaxin receptor
- 49. (New) The method of Claim 48 wherein the host cell is from the AML14.3D10 cell line.